Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy

The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype

Andrea Gaedigk, S.D. Simon, R PEARCE et al. · Clinical Pharmacology & Therapeutics · 2007 · 793 citations

Medicine, Pharmacokinetics, Pharmacology +16

Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes

Matthew P. Goetz, James M. Rae, Vera J. Suman et al. · Journal of Clinical Oncology · 2005 · 786 citations · Full text

Medicine, Oncology, Pharmacology +16

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

Sung Eun Sim, Carl Risinger, Eleni Aklillu et al. · Clinical Pharmacology & Therapeutics · 2006 · 729 citations

Medicine, Pharmacokinetics, Pharmacology +17

Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen

Werner Schroth · JAMA · 2009 · 529 citations · Full text

Medicine, Oncology, Pharmacology +17

Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes

Werner Schroth, Lydia Antoniadou, Péter Fritz et al. · Journal of Clinical Oncology · 2007 · 466 citations

Medicine, Oncology, Pharmacology +17